SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II: In vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man

Xenobiotica

Volumn 32, Issue 3, 2002, Pages 235-250

  Ward, K W ^a   Proksch, J W ^a   Gorycki, P D ^b   Yu, C P ^b   Ho, M Y K ^a   Bush, B D ^b   Levy, M A ^a   Smith, B R ^a  

^a Preclin Drug Discovery Cardiovasc Urogenitary and Oncol Ctr for Excellence in Drug Discovery ^*  (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 PIPERIDINYL) 4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL)IMIDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SB 242235; UNCLASSIFIED DRUG;

ALLOMETRY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; LIVER MICROSOME; MALE; NONHUMAN; RAT; SPECIES DIFFERENCE; URINARY EXCRETION;

ANIMALS; BILE; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; ENZYME INHIBITORS; FECES; HUMANS; IMIDAZOLES; MACACA FASCICULARIS; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RATS; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS; GLOMERULUS;

EID: 0036204914     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250110100711     Document Type: Article

References (21)

1. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced disease
2. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
3. Physiological parameters in laboratory animals and humans
4. In vitro metabolism: Subcellular fractions
5. Suppression of ex vivo cytokine production by SB 242235, a selective inhibitor of p38 MAP kinase
6. In vitro metabolism of the novel antiinflammatory agent 6-(4′fluorophenyl)-5-(4′-pyridyl)-2,3-dihydroimidazo-{2,1-b}- thiazole
7. Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics
8. p38 Mitogen-activated protein kinase inhibitors - Mechanisms and therapeutic potentials
9. Inhibition of p38 MAP kinase as a therapeutic strategy
10. Interspecies scaling of renally secreted drugs
11. Allometric issues in drug development
12. Interspecies scaling: Predicting clearance of drugs in humans. Three different approaches
13. Pharmacokinetics and metabolism of SK&F 86002 in male and female Sprague-Dawley rats
14. Precision-cut tissue slices: Applications in pharmacology and toxicology
15. The allometric approach for interspecies scaling of pharmacokinetic parameters
16. The MAP kinase family: New 'MAPs' for signal transduction pathways and novel targets for drug discovery
17. Pharmacokinetics of triclopyr (3,5,6-trichloro-2-pyridinyloxyacetic acid) in the beagle dog and rhesus monkey: Perspective on the reduced capacity of dogs to excrete this organic acid relative to the rat, monkey, and human
18. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence
19. Disposition of the selective (1A-adrenoceptor antagonist tamsulosin in humans: Comparison of data from interspecies scaling
20. SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I. Preclinical pharmacokinetics
21. Pharmacokinetic principles. Linear and nonlinear